48,830
edits
Difference between revisions of "Malignant mesothelioma"
Jump to navigation
Jump to search
Malignant mesothelioma (view source)
Revision as of 18:43, 10 February 2022
, 18:43, 10 February 2022→Mesothelioma versus mesothelial hyperplasia
| Line 123: | Line 123: | ||
*EMA +ve ~100% (vs. ~10%). | *EMA +ve ~100% (vs. ~10%). | ||
*Desmin -ve ~5% (vs. ~85%). | *Desmin -ve ~5% (vs. ~85%). | ||
*GLUT1 +ve ~50% (vs. ~10%) | *GLUT1 +ve ~50% (vs. ~10%). | ||
*p53 +ve ~50% (vs. ~2%). | *p53 +ve ~50% (vs. ~2%). | ||
*BAP1 -ve | *BAP1 -ve<ref name=pmid29085180>{{cite journal |authors=Pulford E, Huilgol K, Moffat D, Henderson DW, Klebe S |title=Malignant Mesothelioma, BAP1 Immunohistochemistry, and VEGFA: Does BAP1 Have Potential for Early Diagnosis and Assessment of Prognosis? |journal=Dis Markers |volume=2017 |issue= |pages=1310478 |date=2017 |pmid=29085180 |pmc=5612603 |doi=10.1155/2017/1310478 |url=}}</ref> ~57%.<ref name=pmid26226841>{{cite journal |authors=Andrici J, Sheen A, Sioson L, Wardell K, Clarkson A, Watson N, Ahadi MS, Farzin M, Toon CW, Gill AJ |title=Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology |journal=Mod Pathol |volume=28 |issue=10 |pages=1360–8 |date=October 2015 |pmid=26226841 |pmc=4761613 |doi=10.1038/modpathol.2015.87 |url=}}</ref> | ||
Note: | Note: | ||